Trending in Endocrinology: Mounjaro China, Wegovy 7.2 mg and more
Автор: LucidQuest
Загружено: 2025-12-16
Просмотров: 7
Описание: Here’s your Endocrine and Diabetes update. Debiopharm randomizes the first patient in OXTEND-III, testing quarterly octreotide for acromegaly. Abbott and FDA flag FreeStyle Libre 3 sensors for falsely low readings, tied to 736 adverse events and seven deaths outside the U.S. China adds Mounjaro to the NRDL on January 1. EMA extends tirzepatide to children ten years and older and issues a positive opinion for Wegovy 7.2 mg, averaging 20.7 percent weight loss. INHALE-1 misses HbA1c noninferiority; PRISM islet isolation and Brenzavvy rollout advance access.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: